Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement

BACKGROUND: ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. RESULTS: A total of 2309 patients received ROS1 fusion d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Limin, Jiang, Tao, Zhao, Chao, Li, Wei, Li, Xuefei, Zhao, Sha, Liu, Xiaozhen, Jia, Yijun, Yang, Hui, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342729/
https://www.ncbi.nlm.nih.gov/pubmed/27738334
http://dx.doi.org/10.18632/oncotarget.12612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342729/
https://www.ncbi.nlm.nih.gov/pubmed/27738334
http://dx.doi.org/10.18632/oncotarget.12612

Ejemplares similares